Page last updated: 2024-11-05

tranexamic acid and Marfan Syndrome, Type I

tranexamic acid has been researched along with Marfan Syndrome, Type I in 1 studies

Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.

Research Excerpts

ExcerptRelevanceReference
"The utility of tranexamic acid (TXA) in patients with Marfan syndrome (MFS) is uncertain given associated aberrations within the vasculature and clotting cascade."8.12Tranexamic acid use is associated with reduced intraoperative blood loss during spine surgery for Marfan syndrome. ( Ikwuezunma, IA; Margalit, A; Sponseller, PD, 2022)
"The utility of tranexamic acid (TXA) in patients with Marfan syndrome (MFS) is uncertain given associated aberrations within the vasculature and clotting cascade."4.12Tranexamic acid use is associated with reduced intraoperative blood loss during spine surgery for Marfan syndrome. ( Ikwuezunma, IA; Margalit, A; Sponseller, PD, 2022)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Ikwuezunma, IA1
Margalit, A1
Sponseller, PD1

Other Studies

1 other study available for tranexamic acid and Marfan Syndrome, Type I

ArticleYear
Tranexamic acid use is associated with reduced intraoperative blood loss during spine surgery for Marfan syndrome.
    Spine deformity, 2022, Volume: 10, Issue:2

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Marfan Syndrome; Scoliosis; Tranexamic Acid

2022